share_log

東陽光長江藥業:截至二零二四年二月二十九日止月份之股份發行人的證券變動月報表

HEC CJ PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

香港交易所 ·  Mar 1 03:46
Summary by Moomoo AI
宜昌東陽光長江藥業股份有限公司(東陽光長江药业)於2024年2月29日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示,截至2024年2月底,公司的法定/註冊股本總額為879,967,700人民幣,其中H股股份數目維持在653,767,700股,每股面值1人民幣,並無增減變動。內資股部分也維持在226,200,000股,每股面值同樣為1人民幣,本月亦無增減。該報告同時確認,公司沒有股份期權、權證、可換股票據或其他相關股份變動。該報表由聯席公司秘書彭琪雲於2024年3月1日呈交。
宜昌東陽光長江藥業股份有限公司(東陽光長江药业)於2024年2月29日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示,截至2024年2月底,公司的法定/註冊股本總額為879,967,700人民幣,其中H股股份數目維持在653,767,700股,每股面值1人民幣,並無增減變動。內資股部分也維持在226,200,000股,每股面值同樣為1人民幣,本月亦無增減。該報告同時確認,公司沒有股份期權、權證、可換股票據或其他相關股份變動。該報表由聯席公司秘書彭琪雲於2024年3月1日呈交。
YICHANG EAST SUNSHINE CHANGJIANG PHARMACEUTICAL CO., LTD. (EAST SUNSHINE CHANGJIANG PHARMACEUTICALS) FILED ITS LATEST MONTHLY STATEMENT OF CHANGES IN SECURITIES WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON FEBRUARY 29, 2024. The report shows that as of the end of February 2024, the total authorized/registered share capital of the company was RMB879,967,700, of which the number of H shares remained at 653,767,700 shares with an face value of RMB 1 per share, with no increase or decrease. The equity portion also remained at 226,200,000 shares, with a face value of RMB 1 per share, and did not decrease this month. THE REPORT ALSO CONFIRMS THAT THE COMPANY HAS NO CHANGES IN STOCK OPTIONS, WARRANTS, CONVERTIBLE STOCK NOTES OR OTHER RELATED SHARES. The report was submitted by the Joint Secretary of the Joint Undertaking, Peng Chi-yun, on 1 March 2024.
YICHANG EAST SUNSHINE CHANGJIANG PHARMACEUTICAL CO., LTD. (EAST SUNSHINE CHANGJIANG PHARMACEUTICALS) FILED ITS LATEST MONTHLY STATEMENT OF CHANGES IN SECURITIES WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON FEBRUARY 29, 2024. The report shows that as of the end of February 2024, the total authorized/registered share capital of the company was RMB879,967,700, of which the number of H shares remained at 653,767,700 shares with an face value of RMB 1 per share, with no increase or decrease. The equity portion also remained at 226,200,000 shares, with a face value of RMB 1 per share, and did not decrease this month. THE REPORT ALSO CONFIRMS THAT THE COMPANY HAS NO CHANGES IN STOCK OPTIONS, WARRANTS, CONVERTIBLE STOCK NOTES OR OTHER RELATED SHARES. The report was submitted by the Joint Secretary of the Joint Undertaking, Peng Chi-yun, on 1 March 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more